Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS).

Full DD Report for PIRS

You must become a subscriber to view this report.


Recent News from (NASDAQ: PIRS)

Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. to its Board of Directors
BOSTON, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer, respiratory and other diseases, announced today that Pet...
Source: GlobeNewswire
Date: September, 10 2018 08:00
Dosing underway in Pieris Pharma's early-stage study of cancer candidate PRS-343; shares up 3%
The first patient has been dosed in a Phase 1 dose-escalation study evaluating Pieris Pharmaceuticals' ( PIRS +2.9% ) PRS-343, combined with Roche's Tecentriq (atezolizumab), in patients with advanced/metastatic HER2-positive solid tumors. More news on: Pieris Pharmaceuticals, Inc., ...
Source: SeekingAlpha
Date: September, 04 2018 13:03
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc.  (NASDAQ: PIRS) ,   a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer, respiratory and other diseases, announced today that...
Source: GlobeNewswire
Date: September, 04 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-103.493.403.553.39457,898
2018-12-073.503.543.553.40385,670
2018-12-063.593.533.663.46354,440
2018-12-053.553.563.733.43934,831
2018-12-043.553.533.733.43740,825

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1012,945108,95511.8811Cover
2018-12-07125,520188,48166.5956Short
2018-12-0621,84396,48322.6392Cover
2018-12-04228,183367,18562.1439Short
2018-12-0350,239133,03937.7626Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PIRS.


About Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS)

Logo for Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS)

Pieris is a clinical stage biotechnology company advancing its proprietary Anticalin technology to create differentiated drugs that have the potential to be safer and more effective than conventional approaches. Anticalins show promise in addressing high unmet medical needs and expanding the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R amp D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. For more information visit www.pieris.com.

 

Contact Information

 

 

Current Management

  • Stephen S. Yoder / CEO, President
  • Darlene DeptulaHicks / Acting CFO
    • Darlene DeptulaHicks Ms. DeptulaHicks was appointed to the Board of Directors of the Company in April . Ms. DeptulaHicks is a strategic senior financial executive with extensive experience in both public and private companies, including experience in fund raising, mergers and acquisitions, public and private offerings and with operational management focused in life sciences. Since June , Ms. DeptulaHicks has served as Vice President and Chief Financial Officer of Microline Surgical, Inc. From to , Ms. DeptulaHicks was the Vice President, Chief Financial Officer, Treasurer and Secretary of ICAD, Inc. She received her Bachelor of Science in Accounting from Southern New Hampshire University and her MBA from Rivier College. Based upon her extensive financial experience including experience in fund raising, mergers, public companies and life sciences, the Board believes Ms. DeptulaHicks has the appropriate set of skills to serve as a member of our Board.
  • Claus Schalper / VP, Fin.
  • Chau Khuong / Chairman
  • JeanPierre Bizzari /
  • Steven Prelack /
  • Michael Richman /
  • Christina Takke /
  • Stephen S. Yoder /

Current Share Structure

  • Market Cap: $318,823,796 - 05/18/2018
  • Authorized: 300,000,000 - 03/12/2015
  • Issue and Outstanding: 53,855,371 - 03/12/2018

 


Recent Filings from (NASDAQ: PIRS)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 05 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: August, 24 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 09 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: August, 09 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: August, 09 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: August, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: August, 06 2018
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: July, 31 2018

 

 


Daily Technical Chart for (NASDAQ: PIRS)

Daily Technical Chart for (NASDAQ: PIRS)


Stay tuned for daily updates and more on (NASDAQ: PIRS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: PIRS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PIRS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PIRS and does not buy, sell, or trade any shares of PIRS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/